STOCK TITAN

Novavax Inc - NVAX STOCK NEWS

Welcome to our dedicated page for Novavax news (Ticker: NVAX), a resource for investors and traders seeking the latest updates and insights on Novavax stock.

Novavax Inc (NVAX) is a clinical-stage biotechnology company pioneering vaccine development through recombinant nanoparticle technology and its proprietary Matrix-M adjuvant. This dedicated news hub provides investors and industry observers with timely updates on corporate developments, clinical trial progress, and regulatory milestones.

Our curated collection of Novavax news ensures access to official press releases, financial disclosures, and strategic partnership announcements. Users will find updates spanning vaccine candidate advancements, manufacturing expansions, and peer-reviewed research findings. Key content areas include quarterly earnings reports, FDA regulatory submissions, and global health collaborations.

Bookmark this page for streamlined tracking of Novavax's progress in addressing infectious diseases like COVID-19, influenza, and RSV. The resource is regularly updated to serve as your primary source for verified information about NVAX's scientific innovations and market positioning.

Rhea-AI Summary

Novavax has received conditional marketing authorization from the MHRA for its Nuvaxovid™ COVID-19 vaccine in Great Britain, marking it as the first protein-based vaccine authorized there. This decision is based on data from significant clinical trials, including a Phase 3 trial in the U.K. with nearly 15,000 participants and another in the U.S. and Mexico with approximately 30,000 participants, showcasing efficacy rates of 89.7% and 90.4%, respectively. An agreement for 60 million doses was also previously established with the U.K. Vaccines Taskforce.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. has submitted a request for Emergency Use Authorization (EUA) to the FDA for its COVID-19 vaccine candidate, NVX-CoV2373. This request is supported by pivotal clinical trial data demonstrating an overall efficacy of approximately 90% in the PREVENT-19 trial involving 30,000 participants. The vaccine has a favorable safety profile and has received conditional authorization from multiple global regulatory agencies, including the EU and WHO. Novavax aims to provide an alternative vaccine option, leveraging its proprietary protein-based technology and global partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announces an advance purchase agreement with Israel's Ministry of Health for its COVID-19 vaccine, NVX-CoV2373. This agreement includes an initial 5 million doses with an option for an additional 5 million. The vaccine, which has shown high efficacy in ongoing Phase 3 trials, is awaiting regulatory approvals for distribution in Israel. The company has received conditional marketing authorization from the European Union and emergency use listing from the WHO. Novavax continues to monitor safety and efficacy while expanding its manufacturing capabilities worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.71%
Tags
covid-19
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced that Australia's Therapeutic Goods Administration (TGA) has granted provisional registration for NVX-CoV2373, its COVID-19 vaccine. This approval allows for active immunization against COVID-19 in individuals 18 years and older under the brand name Nuvaxovid™. The vaccine's registration is backed by data from pivotal clinical trials involving nearly 30,000 participants. With an advance purchase agreement for 51 million doses in place, Novavax aims to supply Australia while continuing to monitor safety and efficacy as distribution begins.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) and SK bioscience announced the approval of their Nuvaxovid™ COVID-19 vaccine by South Korea's Ministry of Food and Drug Safety for individuals aged 18 and older. This marks Nuvaxovid as the first protein-based COVID-19 vaccine approved in South Korea. SK bioscience is set to manufacture and market the vaccine, supported by an advance purchase agreement for 40 million doses. Novavax anticipates further global authorizations in 2022, including a request for emergency use authorization from the U.S. FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
covid-19
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced a submission for emergency use authorization (EUA) of its COVID-19 vaccine, NVX-CoV2373, to the South African Health Products Regulatory Agency (SAHPRA). The vaccine, developed in partnership with Serum Institute of India, leverages recombinant nanoparticle technology and has shown high efficacy in clinical trials involving over 45,000 participants. It has received authorizations in 170 countries, including the EU and WHO. The company aims to deliver the vaccine in South Africa, pending regulatory approval.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.54%
Tags
covid-19
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, from 9:00 – 9:40 a.m. ET. The conference will focus on Novavax' COVID-19 vaccine candidate NVX-CoV2373. The presentation will be moderated by Eric Joseph, with participation from Novavax President and CEO Stanley C. Erck. Additionally, investor meetings will be held from January 10 to January 12, 2022. An audio replay will be available on Novavax's events page for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.59%
Tags
conferences
-
Rhea-AI Summary

Novavax, Inc. (Nasdaq: NVAX) announced the submission of its final data package for NVX-CoV2373 to the FDA, a key step toward emergency use authorization (EUA) for its COVID-19 vaccine. The CMC package leverages a partnership with the Serum Institute of India and will be supplemented with data from additional sites. NVX-CoV2373, which showed 90.4% efficacy in U.S. and Mexico trials and 89.7% in U.K. trials, is designed for two doses 21 days apart. The company highlights ongoing governmental support and the demand for COVID-19 vaccines amid emerging variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.6%
Tags
covid-19
-
Rhea-AI Summary

Novavax (Nasdaq: NVAX) and Serum Institute of India have received emergency use authorization (EUA) in India for their recombinant nanoparticle protein-based COVID-19 vaccine, Covovax™, featuring the Matrix-M™ adjuvant. This approval aims to expand vaccine options amid India's pandemic response. Covovax™ exhibits over 90% efficacy and a favorable safety profile, with storage requirements compatible with existing vaccine supply chains, making it accessible in hard-to-reach areas. The vaccine has also received EUA in Indonesia and the Philippines, with ongoing regulatory filings in various countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
covid-19
Rhea-AI Summary

Novavax (Nasdaq: NVAX) has expanded its collaboration with SK bioscience to enhance the manufacturing of its COVID-19 vaccine, NVX-CoV2373. The agreement allows SK bioscience to reserve additional manufacturing capacity through 2022, supporting a previously made agreement to supply 40 million doses to the Korean government. SK bioscience is also now authorized to sell NVX-CoV2373 to Thailand and Vietnam. Novavax anticipates a total global manufacturing capacity of 2 billion doses in 2022, demonstrating its commitment to increasing vaccine access globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.97%
Tags
none
Novavax Inc

Nasdaq:NVAX

NVAX Rankings

NVAX Stock Data

965.07M
146.70M
8.8%
60.18%
24.39%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
GAITHERSBURG